IGF-1 and IGF-1BP3 in gastric adenocarcinoma. Preliminary study.

BACKGROUND/AIMS: Insulin-like growth factor-1 (IGF-1) is a mitogenic and anti-apoptotic factor, mainly produced by the liver, which regulates cell proliferation. Most serum IGF-1s are bound with IGF-1BP3. Plasma IGF-1 values are positively related to cancer risk (breast, colon, and lung cancer) and seem to have a prognostic significance in prostatic cancer. The aim of this study is to investigate the relationship between IGF-1, IGF-1BP3 and gastric cancer. METHODOLOGY: IGF-1 and IGF-1BP3 serum levels were measured in 26 consecutive patients (M/F = 15/11, mean age 65 yrs) with histologically proven gastric adenocarcinoma from January 1999 to December 2000. Blood samples were collected at baseline, before surgery with radical intent (total and subtotal gastrectomies + D2 lymphadenectomy), and then at 14th and 50th postoperative days. These values were compared to a control group of healthy people. RESULTS: At baseline was observed a significant increase of IGF-1 serum levels in cancer patients versus control group (p < 0.001). All gastric cancer patients showed IGF-1 over normal limits. After surgery there was a significant decrease of IGF-1 levels (14th day vs. baseline, p = 0.001) that was still present in late postoperative period (50th day). At baseline IGF-1 values were not related to tumor extension or nodal involvement status. Otherwise in postoperative period IGF-1 significantly decreased in earlier stages (N0; T < or = 2) but not in more advanced ones (N+; T > 2). At baseline, IGF-1BP3 values were increased compared to control group but did not significantly decrease after surgery. CONCLUSIONS: IGF-1 values in gastric cancer patients are increased compared to control group, without stratification for stage and nodal status. Moreover radical surgery, with complete tumor ablation, induces a significant decrease in IGF-1 levels, without reach normal limits. Besides at baseline abnormally higher IGF-1BP3 values were observed, suggesting an alteration in IGF-1 and IGF-1BP3 system.

Surgical treatment of hydatid disease of the liver. An experience from outside the endemic area.

Hydatid disease is quite rare in European countries outside the endemic areas. It occurs most frequently in the liver and lungs. Surgery remains the main treatment modality for hydatid disease of the liver. There is still considerable debate as to whether the best approach is conservative surgery or radical surgery in which the cyst is totally removed including the pericyst by total pericystectomy or partial hepatectomy. We report the results of our 15-year experience with this type of surgery. A series of 35 consecutive patients operated on for hydatid disease of the liver from January 1985 to December 2000 was analysed (18 women and 17 men with a mean age of 47.7 years). The most common complaints were pain (59%), hepatomegaly and intra-abdominal masses (37%). The cysts were single in 23 patients and multiple in 12, and were found in the right lobe in 21 cases (59%), in the left lobe in 9 cases (26%), and in both lobes in 5 (15%). In one patient (2.8%), concomitant extrahepatic (splenic) disease was present. The diameter of the cysts ranged from 3.5 to 20 cm (mean value: 9.5 cm). Patients were subdivided according to the kind of surgery (radical versus conservative) and period of operation (group 1: 1985-1992; group 2: 1993-2000). With the increase in surgical skills and the advent of new techniques, radical surgery (12 cystoperistectomies, 3 left lobectomies and 3 segmentectomies) came to be performed more frequently than conservative surgery in the second period (18/20 in group 2 versus in 7/15 group 1) with low complication rates, a 3.7% mortality rate and similar operative time (175 min versus 145 min) and hospital stay (16.8 days versus 19.2 days) as compared to the conservative approach. The policy of applying radical surgery whenever feasible can be implemented with acceptable morbidity and near zero mortality. Radical surgery, however, needs to be applied judiciously, and there is still an important role for conservative surgery.

Preoperative selective endoscopic retrograde cholangiopancreatography and laparoscopic cholecystectomy without cholangiography.

The aim of this study was to show that laparoscopic cholecystectomy can be performed safely without routine intraoperative cholangiography. We performed a retrospective analysis of 1750 consecutive patients (1170 females and 580 males with a mean age of 51 years) who underwent laparoscopic cholecystectomy between January 1991 and January 2000. In all, 193 patients (11%) were selected to undergo preoperative endoscopic retrograde cholangiopancreatography (ERCP) on the basis of several criteria for risk of stones. No patients underwent intraoperative cholangiography. ERCP allowed us to make a diagnosis of biliary stones in 62.7% (121 cases). Extraction of the stones was successful in 96% of the cases. In 12% of cases ERCP findings were normal; in the remaining 26.3%, useful diagnostic information was obtained. There were three complications (bleeding and pancreatitis) after endoscopy (complication rate: 1.5%). Laparoscopic cholecystectomy was successful in 92.7% of patients, with a postoperative morbidity rate of 3% (0.5% of major complications). There were no deaths in this series. During a mean follow-up of 60 months (range, 12-120), 7 patients (0.43%) were found to have residual biliary stones (5 had not had preoperative ERCP). The study confirms the hypothesis that laparoscopic cholecystectomy can be safely performed without routine intraoperative cholangiography, with selective use of preoperative ERCP.